Mechanisms of Anabolic Osteoporosis Therapy
ConditionOsteoporosis, Postmenopausal
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age45+
SponsorMassachusetts General Hospital
About this trial
The aim of this study is to investigate the effect of romosozumab on bone cells during early and late phases of treatment.
Eligibility criteria
Qualifiers
Female aged > 45 years
> 36 since last spontaneous menses
> 36 months since hysterectomy, plus serum FSH > 40 units / liter if < 60 years
Disqualifiers
renal disease (stage 4 CKD)
elevated blood PTH (intact PTH > 77 pg/ml).
serum 25-OH vitamin D < 20 ng/ml
major psychiatric disease that in the opinion of the investigator would preclude the subject from providing adequate informed consent or completing the protocol procedures.
Trial design
Treatments tested in this trial
- early versus late biopsy
Treatment groups
16 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov